QC
SMMT icon

Quantessence Capital’s Summit Therapeutics SMMT Stock Holding History

Quantessence Capital’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-36,187
Closed -$770K – 294
2025
Q2 		$770K Buy
+36,187
New +$825K 0.23% 96

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
ACL
APEIRON Capital Ltd Hong Kong $107M AUM 9.59% 1-Year Est. Return

Quantessence Capital's SMMT Position: Q3 2025 in Review

Quantessence Capital sold out of Summit Therapeutics (SMMT) in Q3 2025, closing a stake of 36,187 shares — an estimated $770K sold.

Quantessence Capital first reported a position in SMMT in Q2 2025 and held it in 1 quarter. The position peaked at $770K in Q2 2025. 232 funds tracked by Wall St. Rank hold SMMT as of Q3 2025.

  • Quantessence Capital reported no remaining Summit Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Quantessence Capital sold 36,187 Summit Therapeutics shares in Q3 2025, an estimated $770K.
  • Quantessence Capital first reported a position in Summit Therapeutics in Q2 2025 and held it in 1 quarter.
  • Quantessence Capital's Summit Therapeutics position peaked at $770K in Q2 2025.
  • 232 funds tracked by Wall St. Rank held Summit Therapeutics as of Q3 2025.

Based on Quantessence Capital's 13F filing for Q3 2025, filed 14 Nov 2025.